New #Publication: #PADMA provides first prospective randomized evidence that #palbociclib + #ET is superior to standard single-agent chemotherapy as first-line treatment for HR+/HER2- metastatic breast cancer in terms of treatment durability and disease control. www.sciencedirect.com/science/arti...

#ESMOBC: new analyses from the Phase III #INAVO120 trial evaluating inavolisib in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, HR-positive/HER2-negative endocrine-resistant advanced breast cancer. Visit our website: www.gbg.de/en/news/deta...

New data from #ESMOBC The #GeparPiPPa study showed a manageable safety profile for chemotherapy-free treatment with #inavolisib, endocrine therapy, and dual #HER2 blockade in HR+/HER2+/PIK3CA-mutant early breast cancer, supporting more personalized treatment strategies. #BreastCancer #GBG www.gbg.de

New insights from #ESMOBC: A modified Sinn regression grade combining tumor response and nodal status improved prognostic stratification after neoadjuvant therapy in breast cancer, supporting more personalized treatment decisions. #BreastCancer #GBG Visit our website: www.gbg.de

🧬 Today on #WorldCancerDay our thoughts are with everyone who is affected directly or indirectly by #cancer. At the same time, we want to highlight the enormous potential that #science now offers - especially for people with #breastcancer: #Molecular #Testing www.gbg.de/en/news/deta...

🔔 Reminder: Join us on March 12–13, 2026 for the 23rd Annual Scientific Meeting 2026 #ASM, a 2-day international #conference focusing on breast cancer. 👉 Registration is open now – make sure to secure the Early Bird rate by January 15: extern.gbg.events

🔍 #SABCS2025: #INSEMA Trial – #Radiotherapy Analysis (presented by Guido Hildebrandt) Today’s presentation offered important insights into how radiotherapy was actually applied among patients undergoing breast-conserving surgery with or without sentinel lymph node biopsy #SLNB in the INSEMA trial.

#SABCS2025 Update: #INSEMA – Secondary results presented by Toralf Reimer INSEMA Rando2 adds robust data on the oncological #safety of omitting cALND in patients with positive SLNB, under conditions of strict regional nodal irradiation #RNI and #radiotherapy quality assurance.

📣 Meet #GBG at #SABCS2025 – Highlights for December 11! A full and inspiring third day at the SABCS brought important new insights into #axillary #surgery, #radiotherapy strategies, #translational #biomarkers, and international collaborations shaping the future of #breast #cancer care.

At #SABCS2025, new translational results from the #NSABP B-59/GBG-96- #GeparDouze trial were presented by Carsten Denkert, highlighting how #TIL levels and molecular #TNBC subtypes shape response to #neoadjuvant immune-chemotherapy. ➡️ Full details are available here: www.gbg.de/news/detail/...

📢 Hot from the Press: Now published in #NEJM! We are excited to share that the pivotal DESTINY-Breast05 data „Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer“ presented by Sibylle Loibl at #SABCS2025, is now available. 🔗 Read the full NEJM article: www.nejm.org/doi/full/10....

#SABCS2025: S. Loibl presented additional efficacy and safety data from the DESTINY-Breast05 trial, evaluating trastuzumab deruxtecan vs trastuzumab emtansine as post-NACT for pts with high-risk HER2-positive early breast cancer who did not achieve a pCR after standard NACT and anti-HER2 therapy.

📣 Meet #GBG at #SABCS2025 – Highlights for December 10! Another strong day for GBG at the San Antonio Breast Cancer Symposium with key data on #HER2+ early breast cancer, #TNBC immuno- #chemotherapy response #biology, and multiple high-impact external collaborations.

🧬 #SABCS2025 | Impact of Checkpoint Inhibition on Fertility in Young Women with Early TNBC Key Findings from the #NSABP B-59/GBG-96-GeparDouze Substudy presented by Mattea Reinisch ➡️ For more details and the full presentation, please visit the #GBG website: www.gbg.de/news/detail/... #GeparDouze

At #SABCS2025, Brooke M. Felsheim presented a pooled analysis of three major randomized trials - #BrighTNess, #CALGB40603, and #GeparSixto—providing one of the most comprehensive evaluations to date of #carboplatin in early-stage triple-negative breast cancer (TNBC).

📢 Key Findings from Our #SABCS2025 Presentation Prognostic Markers in Residual TNBC After Neoadjuvant Chemotherapy – Pooled Analysis from Nine #GBG/AGO-B Trials Presented by Johannes Holtschmidt ➡️ For more details and the full presentation, please visit the GBG website: www.gbg.de/news/detail/...

📣 Meet #GBG at #SABCS2025 – Highlights for December 9! 3 high-impact Rapid Fire Presentations featuring new analyses from leading #neoadjuvant and #immunotherapy trials. All presentation materials will be made available after the conference here: www.gbg.de/news/detail/...

📢 The #TAMENDOX study #GBG91 has been published in #CCR, presenting new evidence on optimizing #endocrine therapy in patients with impaired #tamoxifen metabolism. Read full text here: aacrjournals.org/clincancerre...

„Highly Cited“ Goethe-Forscher*innen 2025 ⤵️ ▪️ Prof. Dr. Florian Büttner ▪️ Prof. Dr. Ivan Đikić ▪️ Prof. Dr. Florian Greten @loewe-fci.bsky.social ▪️ Prof. Dr. Gerhard Hummer @mpibp.bsky.social ▪️ apl. Prof. Dr. Sibylle Loibl @gbg.de ▪️ Prof. Dr. Stefan Offermanns ▪️ Prof. Dr. Klement Tockner @sgn.one

PinkOctober – Research Brings Hope: #INSEMA Study #GBG75 📖 Most recent results have been published in #NEJM: www.nejm.org/doi/full/10.... Exciting news: the latest INSEMA data will be presented as an Oral Presentation at the San Antonio Breast Cancer Symposium #SABCS2025 this December.

#NeoRad study #GBG116: phase III trial investigating whether #preoperative radiotherapy can improve disease-free survival compared to #postoperative #radiotherapy after #neoadjuvant #chemotherapy in patients with high-risk early breast cancer. 👉 More information: www.gbg.de/en/trials/neorad

#PinkOctober - #ASCENT-05: Phase III study investigates whether #Sacituzumab #Govitecan in combination with #Pembrolizumab can further improve outcomes compared to physician’s choice of standard therapy in pts with early TNBC who still have residual invasive disease after NACT and surgery

Today at the #DGHO Annual Meeting 2025 #Cologne: #GBG presents exciting new research on combination therapy for #BRCA-mutated #breastcancer! Proud to share the #ELEMENT study #GBG114 — a randomized phase II trial exploring whether adding the oral #SERD #elacestrant to the #PARP inhibitor #olaparib.

Published in #BCR this year introduces a powerfulprediction model for pathological complete response in #HER2-negative #breastcancer, developed using data from more than 1,100 pts: observational Hannover Breast Cancer Study and randomized #GeparSepto #GBG69 and #GeparOcto #GBG84 #clinicaltrials.

In this #BreastCancerAwarenessMonth, we are excited to share that #GBG will have a strong scientific presence at the San Antonio Breast Cancer Symposium #SABCS2025 — one of the most important international meetings in breast cancer research. 💡

#GeparPiPPa #GBG105 investigates #neoadjuvant #endocrine therapy in combination with #trastuzumab and #pertuzumab, with or without the #PI3K inhibitor #inavolisib, in patients with HER2-positive, HR-positive, PIK3CA-mutated primary breast cancer. Learn more about the study www.gbg.de/en/trials/ge...

#BreastCancerAwarenessMonth2025: This October, as we raise awareness for #breastcancer and highlight the importance of long-term patient care, we invite all former study participants to take part in the #GBG071 #Registry 👉 Learn more and register here: www.gbg.de/en/trials/re...

#Flamingo-01 #GBG111: a global phase III, randomized, placebo-controlled study investigating the GLSI-100 immunotherapy in HLA-A*02-positive and HER2/neu-positive breast cancer patients who remain at high risk of #recurrence after completing both #neoadjuvant and #adjuvant standard therapy.

#PinkOctober: The study reveals that luminal breast tumors can dynamically change under #neoadjuvant #chemotherapy - with aggressive #Luminal B tumors often transitioning into a less aggressive Luminal A type. Read full publication here: www.cell.com/cancer-cell/...

#PinkOctober | #ESMO2025 #BMBC registry #GBG79 as poster presentation: The results highlight the importance of retesting #HER2 status in #metastatic sites and open the door to new, targeted treatment opportunities — even for patients previously classified as HER2-negative.

#ESMO2025 #GBG presented long-term results from #GeparNuevo trial #GBG96 providing new insights into the role of immunotherapy in early #TNBC - survival benefit for #PD-L1 inhibitor was showed. This is the only trial with benefit in combination with dose-dense chemotherapy without carboplatin!

#DESTINY-Breast05 trial #GBG103 at #ESMO2025: T-DXd as a potential new #SOC? The phase III study demonstrated statistically significant and clinically meaningful improvement in #IDFS #DFS with #T-DXd vs #T-DM1 in pts with high-risk #HER2-positive eBC who had residual invasive disease.

#GBG at #ESMO2025: As one of the leading research groups in breast cancer, we are proud to contribute to several presentations and discussions that will shape the future of oncology research. We’re looking forward to inspiring sessions, great scientific exchange at #ESMO25

#BreastCancerAwarenessWeek for Men with #BreastCancer 💙 As part of this awareness week, the #GBG would like to highlight a crucial topic for all individuals affected by breast cancer: molecular and genetic testing. Learn more: www.gbg.de/news/detail/... Workshop-Link: www.youtube.com/watch?v=_tIP...

#PinkOctober Spotlight: The #ETERNITY-B #Registry #GBG107 – a prospective and retrospective follow-up project dedicated to understanding the long-term #safety and #efficacy of #treatments used in #GBG #clinicaltrials for early-stage #breastcancer 👉 Learn more: www.gbg.de/en/trials/et...

#LOBSTER trial #GBG118 for pts with #lobular #breastcancer: It investigates whether the combination of #capivasertib + #fulvestrant can achieve a stronger therapeutic effect than fulvestrant alone – aiming to reduce #recurrence risk and improve quality of life. 👉 www.gbg.de/en/trials/lo...

#PinkOctober2025: #Leptomeningeal #metastases #LM remain one of the most severe complications in breast cancer, associated with a markedly poorer #prognosis than brain metastases without LM. This large #registry analysis highlights an urgent unmet clinical need: pmc.ncbi.nlm.nih.gov/articles/PMC...

#PinkOctober 2025 | Spotlight on BMBC Study – Understanding Brain #Metastases in Breast Cancer #BMBC 📰 What’s next: We’re excited to announce that new analyses from the BMBC registry will be presented at #ESMO25 and #SABCS25. Stay tuned for more details in the coming days! www.gbg.de/en/trials/bmbc

Hot from the Press | #BreastCancerScreening Works – New Data Show Significant Reduction in Mortality. Findings clearly demonstrate: Mammography screening saves lives – and remains a key pillar in reducing #breastcancer mortality in Germany: ZEBra-MSP project doris.bfs.de/jspui/handle...

#PinkOctober | Understanding #BreastCancer in #Pregnancy #BCP, #GBG29: With the trend toward later motherhood, the incidence of breast cancer during pregnancy is slowly increasing. Yet, data on how the disease and its treatment affect both mother and child remain limited. BCP aims to fill this gap.

#PinkOctober | #Publication on Breast Cancer Diagnosed During #Pregnancy in #npjBreastCancer: Findings provide important insights into the biology of pregnancy-associated breast cancer #PrBC and may guide future strategies for patient care. 👉 pmc.ncbi.nlm.nih.gov/articles/PMC...

#PinkOctober: #Cambria-2 Trial #GBG115: international phase III clinical trial exploring whether #SERD #Camizestrant can offer better protection against recurrence than standard adjuvant endocrine therapy in pts with early-stage ER+/HER2- breast cancer www.gbg.de/en/trials/ca...

#PinkOctober: we highlight the #Cambria-1 #GBG110 trial – a study that offers new perspectives for pts with early-stage ER+/HER2- #breastcancer Goal: Compare invasive breast cancer-free survival between pts receiving #Camizestrant and those continuing on standard therapy 👉 www.gbg.de/en/trials/ca...

In The Lancet Regional Health – Europe: important real-world insights into the prevalence and prognosis of pts with early ER+/HER2- breast cancer who may be eligible for adjuvant CDK4/6 inhibitors: #monarchE and #NATALEE compared to #PANTHER trial #GBG53 www.sciencedirect.com/science/arti...

Pink October: #GBG highlight a special offer: interactive #workshops “Brustkrebs kompakt erklärt” These online workshops are designed to provide scientifically sound, practice-oriented knowledge at the highest level, aligned with the latest state of #BreastCancer research: www.workshops.gbg.events

Spotlight on the #MOMENTUM study #GBG 108 – a prospective, non-interventional, translational registry study. 🧬 By analyzing #tumor tissue and #ctDNA, we seek to uncover how tumors evolve over time – and how therapies can be made more precise and effective. 👉 www.gbg.de/studien/mome...

Progress in breast cancer (BC) research: #TAXIS - phase III trial exploring innovative treatment strategies for pts with clinically node-positive BC. The study evaluates tailored axillary surgery +/- lymph node dissection, followed by radiotherapy. Publication: www.ejcancer.com/article/S095... #GBG

Driving Innovation in Breast Cancer Research! At #GBG, we cover the full spectrum of breast cancer #treatment – always striving to improve outcomes for patients. Our strength lies in investigator-initiated, academically driven trials, complemented by service studies for our partners. www.gbg.de

📰 Final survival results of #PENELOPE-B trial: While routine adjuvant palbociclib cannot be recommended for all HR+/HER2− early breast cancers (BC), the results point to importance of histological subtypes. For lobular BC CDK4/6 inhibition hold new promise: www.annalsofoncology.org/article/S092...

Today marks the start of Pink October – the international Breast Cancer Awareness Month: To provide guidance and clarity, we are sharing an insight into the #GBG patient journey slider from our homepage: www.gbg.de/en/patients #BreastCancerAwarenessMonth #PinkOctober #BreastCancer #ClinicalTrials